<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>PROMETHAZINE DM - dextromethorphan hydrobromide  and promethazine hydrochloride  syrup </strong><br>Stat Rx USA<br></p></div>
<h1>Promethazine DM (Dextromethorphan Hydrobromide and Promethazine Hydrochloride)  syrup  </h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-1"></a><p></p>
<a href="#section-"></a><a href="#section-"></a>DESCRIPTION<p class="First">Each 5 mL (one teaspoonful), for oral administration contains: 
Dextromethorphan hydrobromide 15 mg; promethazine hydrochloride 6.25 mg. Alcohol 
7%.</p>
<p>Inactive Ingredients: Ascorbic acid, citric acid, D and C yellow #10, 
FD and C yellow #6, menthol, methylparaben, orange pineapple flavor, propylene 
glycol, propylparaben, purified water, saccharin sodium, sodium benzoate, sodium 
citrate and sucrose.</p>
<p>Dextromethorphan hydrobromide is a salt of the methyl ether of the 
dextrorotatory isomer of levorphanol, a narcotic analgesic. It is chemically 
designated as 3-methoxy-17-methyl-9α, 13α, 14α-morphinan hydrobromide 
monohydrate. Dextromethorphan hydrobromide occurs as white crystals sparingly 
soluble in water and freely soluble in alcohol. It has a molecular weight of 
370.32, a molecular formula of C<span class="Sub">18</span>H<span class="Sub">25</span>NO•HBr•H<span class="Sub">2</span>O, and the following 
structural formula:</p>
<br><p><img alt="Structure Image 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d2853595-d913-4332-b15f-49211a7b6667&amp;name=PromethDM_struct1.jpg"></p>
<p></p>
<p><br></p>
<p>Promethazine is a racemic compound. Promethazine hydrochloride, a 
phenothiazine derivative, is chemically designated as 10<span class="Italics">H</span>-Phenothiazine-10-ethanamine, <span class="Italics">N</span>,<span class="Italics">N</span>, 
α-trimethyl-monohydrochloride.</p>
<p>Promethazine hydrochloride occurs as a white to <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">faint</span> yellow, practically 
odorless, crystalline powder which slowly oxidizes and turns blue on prolonged 
exposure to air. It is soluble in water and freely soluble in alcohol. It has a 
molecular weight of 320.88, a molecular formula of C<span class="Sub">17</span>H<span class="Sub">20</span>N<span class="Sub">2</span>S•HCI, and 
the following structural formula:</p>
<br><p><img alt="Structure Image 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d2853595-d913-4332-b15f-49211a7b6667&amp;name=PromethDM_struct2.jpg"><br></p>
<p><br></p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-2"></a><p></p>
<a href="http://"></a>CLINICAL PHARMACOLOGY<a href="http://"></a><a href="http://"></a>Dextromethorphan:<p class="First">Dextromethorphan is an antitussive agent and, unlike the isomeric 
levorphanol, it has no analgesic or addictive properties.</p>
<p>The drug acts centrally and elevates the threshold for <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span>. It is about 
equal to codeine in depressing the <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> reflex. In therapeutic dosage 
dextromethorphan does not inhibit ciliary activity.</p>
<p>Dextromethorphan is rapidly absorbed from the gastrointestinal tract and 
exerts its effect in 15 to 30 minutes. The duration of action after oral 
administration is approximately three to six hours. Dextromethorphan is 
metabolized primarily by liver enzymes undergoing O-demethylation, 
N-demethylation, and partial conjugation with glucuronic acid and sulfate. In 
humans, (+)-3-hydroxy-N-methyl-morphinan, (+)-3-hydroxymorphinan, and traces of 
unmetabolized drug were found in urine after oral administration.</p>
<a href="http://"></a><a href="http://"></a>Promethazine:<p>Promethazine is a phenothiazine derivative which differs 
structurally from the antipsychotic phenothiazines by the presence of a branched 
side chain and no ring substitution. It is thought that this configuration is 
responsible for its relative lack (1/10 that of chlorpromazine) of dopamine 
antagonist properties.</p>
<p>Promethazine is an H<span class="Sub">1</span> receptor blocking agent. In 
addition to its antihistaminic action, it provides clinically useful sedative 
and antiemetic effects.</p>
<p>Promethazine is well absorbed from the gastrointestinal tract. Clinical 
effects are apparent within 20 minutes after oral administration and generally 
last four to six hours, although they may persist as long as 12 hours. 
Promethazine is metabolized by the liver to a variety of compounds; the 
sulfoxides of promethazine and N-demethylpromethazine are the predominant 
metabolites appearing in the urine.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-3"></a><p></p>
<a href="http://"></a>INDICATIONS AND USAGE<p class="First">Promethazine hydrochloride and dextromethorphan hydrobromide 
syrup is indicated for the temporary relief of <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughs</span> and upper respiratory 
symptoms associated with <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> or the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-4"></a><p></p>
<a href="http://"></a>CONTRAINDICATIONS<p class="First">Dextromethorphan should not be used in patients receiving a 
monoamine oxidase inhibitor (MAOI) (see <span class="Bold"><span class="Emphasis"><a href="#section-10">PRECAUTIONS,</a></span></span><span class="Bold"><span class="Emphasis"><a href="#section-10.3"> Drug 
Interactions</a></span></span>).</p>
<p>Promethazine is contraindicated in <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">comatose</span> states, and in individuals known 
to be hypersensitive or to have had an idiosyncratic reaction to promethazine or 
to other phenothiazines.</p>
<p>Antihistamines are contraindicated for use in the treatment of lower 
respiratory tract symptoms, including <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-5"></a><p></p>
<p class="First">WARNINGS</p>
<a href="http://"></a>Dextromethorphan:<p>Administration of dextromethorphan may be accompanied by 
histamine release and should be used with caution in <span class="product-label-link" type="condition" conceptid="4019380" conceptname="Atopy">atopic</span> children.</p>
<a href="http://"></a><a href="http://"></a>Promethazine:<a href="http://"></a><a href="http://"></a><span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS Depression</span><p>Promethazine may impair the mental and/or physical abilities 
required for the performance of potentially hazardous tasks, such as driving a 
vehicle or operating machinery. The impairment may be amplified by concomitant 
use of other central nervous system depressants such as alcohol, 
sedatives/hypnotics (including barbiturates), narcotics, narcotic analgesics, 
general anesthetics, tricyclic antidepressants, and tranquilizers; therefore, 
such agents should either be eliminated or given in reduced dosage in the 
presence of promethazine HCl (see <span class="Bold"><span class="Emphasis"><a href="#section-10">PRECAUTIONS -</a></span></span><span class="Bold"><span class="Emphasis"><a href="#section-10.2"> Information For 
Patients</a></span></span> and <span class="Bold"><span class="Emphasis"><a href="#section-10.3">Drug Interactions</a></span></span>).</p>
<a href="http://"></a><a href="http://"></a><span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory Depression</span><p>Promethazine may lead to potentially fatal respiratory 
<span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>.</p>
<p>Use of promethazine in patients with compromised respiratory function (e.g., 
<span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span>, <span class="product-label-link" type="condition" conceptid="313459" conceptname="Sleep apnea">sleep apnea</span>) should be avoided.</p>
<a href="http://"></a><a href="http://"></a>Lower <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizure</span> Threshold<p>Promethazine may lower <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> threshold. It should be used with 
caution in persons with <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> disorders or in persons who are using 
concomitant medications, such as narcotics or local anesthetics, which may also 
affect <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> threshold.</p>
<a href="http://"></a><a href="http://"></a><span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Bone Marrow Depression</span><p>Promethazine should be used with caution in patients with bone 
<span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">marrow depression</span>. <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span> and <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span> have been reported, usually 
when promethazine HCl has been used in association with other known marrow toxic 
agents.</p>
<a href="http://"></a><a href="http://"></a><span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span><p>A potentially fatal symptom complex sometimes referred to as 
<span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> (NMS) has been reported in association with 
promethazine HCl alone or in combination with antipsychotic drugs. Clinical 
manifestations of NMS are <span class="product-label-link" type="condition" conceptid="4260205" conceptname="Hyperpyrexia">hyperpyrexia</span>, <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">muscle rigidity</span>, altered mental status 
and evidence of <span class="product-label-link" type="condition" conceptid="434633" conceptname="Disorder of autonomic nervous system">autonomic instability</span> (<span class="product-label-link" type="condition" conceptid="4088122" conceptname="Heart irregular">irregular pulse</span> or blood pressure, 
<span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span> and <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac dysrhythmias</span>).</p>
<p>The diagnostic evaluation of patients with this syndrome is complicated. In 
arriving at a diagnosis, it is important to identify cases where the clinical 
presentation includes both serious medical illness (e.g., <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, systemic 
<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, etc.) and untreated or inadequately treated extrapyramidal signs and 
symptoms (EPS). Other important considerations in the differential diagnosis 
include central anticholinergic toxicity, <span class="product-label-link" type="condition" conceptid="4181404" conceptname="Heat stroke">heat stroke</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">drug fever</span> and primary 
central nervous system (CNS) pathology.</p>
<p>The management of NMS should include 1) immediate discontinuation of 
promethazine HCl, antipsychotic drugs, if any, and other drugs not essential to 
concurrent therapy, 2) intensive symptomatic treatment and medical monitoring, 
and 3) treatment of any concomitant serious medical problems for which specific 
treatments are available. There is no general agreement about specific 
pharmacological treatment regimens for uncomplicated NMS.</p>
<p>Since recurrences of NMS have been reported with phenothiazines, the 
reintroduction of promethazine HCl should be carefully considered.</p>
<a href="http://"></a><a href="http://"></a>Use In Pediatric Patients<p><span class="Bold"><span class="Emphasis">PROMETHAZINE PRODUCTS ARE 
CONTRAINDICATED FOR USE IN PEDIATRIC PATIENTS LESS THAN TWO YEARS OF 
AGE.</span></span></p>
<p><span class="Bold"><span class="Emphasis">CAUTION SHOULD BE EXERCISED WHEN 
ADMINISTERING PROMETHAZINE PRODUCTS TO PEDIATRIC PATIENTS 2 YEARS OF AGE AND 
OLDER BECAUSE OF THE POTENTIAL FOR FATAL <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">RESPIRATORY DEPRESSION</span>. RESPIRATORY 
<span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">DEPRESSION</span> AND <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">APNEA</span>, SOMETIMES ASSOCIATED WITH <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">DEATH</span>, ARE STRONGLY ASSOCIATED 
WITH PROMETHAZINE PRODUCTS AND ARE NOT DIRECTLY RELATED TO INDIVIDUALIZED 
WEIGHT-BASED DOSING, WHICH MIGHT OTHERWISE PERMIT SAFE ADMINISTRATION. 
CONCOMITANT ADMINISTRATION OF PROMETHAZINE PRODUCTS WITH OTHER RESPIRATORY 
DEPRESSANTS HAS AN ASSOCIATION WITH <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">RESPIRATORY DEPRESSION</span>, AND SOMETIMES <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">DEATH</span>, 
IN PEDIATRIC PATIENTS.</span></span></p>
<p><span class="Bold"><span class="Emphasis">ANTIEMETICS ARE NOT RECOMMENDED FOR 
TREATMENT OF UNCOMPLICATED <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">VOMITING</span> IN PEDIATRIC PATIENTS, AND THEIR USE SHOULD 
BE LIMITED TO PROLONGED <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">VOMITING</span> OF KNOWN ETIOLOGY. THE <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">EXTRAPYRAMIDAL SYMPTOMS</span> 
WHICH CAN OCCUR SECONDARY TO PROMETHAZINE HYDROCHLORIDE ADMINISTRATION MAY BE 
<span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">CONFUSED</span> WITH THE CNS SIGNS OF UNDIAGNOSED PRIMARY DISEASE, e.g., <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">ENCEPHALOPATHY</span> 
OR REYE'S SYNDROME. THE USE OF PROMETHAZINE PRODUCTS SHOULD BE AVOIDED IN 
PEDIATRIC PATIENTS WHOSE SIGNS AND SYMPTOMS MAY SUGGEST REYE'S SYNDROME OR OTHER 
<span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">HEPATIC DISEASES</span>.</span></span></p>
<p>Excessively large dosages of antihistamines, including promethazine 
hydrochloride, in pediatric patients may cause <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span> (see <span class="Bold"><span class="Emphasis"><a href="#section-13">OVERDOSAGE</a></span></span>). <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">Hallucinations</span> and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> 
have occurred with therapeutic doses and <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> of promethazine hydrochloride 
in pediatric patients. In pediatric patients who are acutely ill associated with 
<span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, there is an increased susceptibility to <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonias</span> with the use of 
promethazine HCl.</p>
<a href="http://"></a><a href="http://"></a>Other Considerations<p>Administration of promethazine has been associated with reported 
<span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-6"></a><p></p>
<a href="http://"></a>PRECAUTIONS<p class="First">Animal reproduction studies have not been conducted with the drug 
combination–promethazine and dextromethorphan. It is not known whether this drug 
combination can cause fetal harm when administered to a pregnant woman or can 
affect reproduction capacity. Promethazine and dextromethorphan should be given 
to a pregnant woman only if clearly needed.</p>
<a href="http://"></a><a href="http://"></a>General:<p>Dextromethorphan should be used with caution in sedated patients, 
in the debilitated, and in patients confined to the supine position.</p>
<p>Drugs having anticholinergic properties should be used with caution in 
patients with narrow-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">prostatic hypertrophy</span>, stenosing peptic 
<span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span>, pyloroduodenal obstruction, and bladder-neck obstruction.</p>
<p>Promethazine should be used cautiously in persons with cardiovascular disease 
or with impairment of liver function.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-7"></a><p></p>
<a href="http://"></a>ADVERSE REACTIONS<p class="First"><span class="Bold"><span class="Emphasis">Dextromethorphan:</span></span></p>
<p>Dextromethorphan hydrobromide occasionally causes slight <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, 
<span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, and <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disturbances</span>.</p>
<p><span class="Bold"><span class="Emphasis">Promethazine:</span></span></p>
<p>Central Nervous System – <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Drowsiness</span> is the most prominent CNS effect of this 
drug. Sedation, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>; <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, 
<span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>, and <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal symptoms</span> such as <span class="product-label-link" type="condition" conceptid="4205592" conceptname="Oculogyric crisis">oculogyric crisis</span>, 
<span class="product-label-link" type="condition" conceptid="440814" conceptname="Torticollis">torticollis</span>, and tongue protrusion; <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">lassitude</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, <span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">incoordination</span>, 
<span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, convulsive 
<span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, excitation, <span class="product-label-link" type="condition" conceptid="4085823" conceptname="Catatonia">catatonic</span>-like states, <span class="product-label-link" type="condition" conceptid="434889" conceptname="Dissociative disorder">hysteria</span>. <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">Hallucinations</span> have also 
been reported.</p>
<p>Cardiovascular – Increased or decreased blood pressure, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, 
<span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, faintness.</p>
<p>Dermatologic – <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">Dermatitis</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>.</p>
<p>Hematologic – <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="4119134" conceptname="Thrombocytopenic purpura">thrombocytopenic purpura</span>, 
<span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>.</p>
<p>Gastrointestinal – <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry mouth</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>.</p>
<p>Respiratory – <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span>, <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal stuffiness</span>, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> (potentially 
fatal) and <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span> (potentially fatal). (See <span class="Bold"><span class="Emphasis"><a href="#section-7">WARNINGS –</a></span></span><span class="Bold"><span class="Emphasis"><a href="#section-7.3"> Promethazine; 
</a></span></span><span class="Emphasis"><a href="#section-7.3.2">Respiratory 
<span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></a></span>.)</p>
<p>Other – <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioneurotic edema</span>. <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic malignant syndrome</span> (potentially 
fatal) has also been reported. (See <span class="Bold"><span class="Emphasis"><a href="#section-7">WARNINGS –</a></span></span><span class="Bold"><span class="Emphasis"><a href="#section-7.3"> Promethazine; </a></span></span><span class="Emphasis"><a href="#section-7.3.5"><span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant</span> 
Syndrome</a></span>.)</p>
<p>Paradoxical Reactions – <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">Hyperexcitability</span> and abnormal movements have been 
reported in patients following a single administration of promethazine HCl. 
Consideration should be given to the discontinuation of promethazine HCl and to 
the use of other drugs if these reactions occur. <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory depression</span>, 
<span class="product-label-link" type="condition" conceptid="4009184" conceptname="Dream anxiety disorder">nightmares</span>, <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>, and <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitated</span> behavior have also been reported in some of 
these patients.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-8"></a><p></p>
<a href="http://"></a>OVERDOSAGE<a href="http://"></a><a href="http://"></a>Dextromethorphan:<p class="First">Dextromethorphan may produce central <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">excitement</span> and mental 
<span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>. Very high doses may produce <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>. One case of toxic 
<span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> (<span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactivity</span>, marked visual and <span class="product-label-link" type="condition" conceptid="4164151" conceptname="Auditory hallucinations">auditory hallucinations</span>) after 
ingestion of a single dose of 20 tablets (300 mg) of dextromethorphan has been 
reported.</p>
<a href="http://"></a><a href="http://"></a>Promethazine:<p>Signs and symptoms of overdosage with promethazine HCl range from 
mild <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> of the central nervous system and cardiovascular system to 
profound <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">unconsciousness</span>, and <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span>. 
Other reported reactions include <span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">hyperreflexia</span>, <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">hypertonia</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="4259277" conceptname="Athetosis">athetosis</span>, 
and extensor-plantar reflexes (Babinski reflex).</p>
<p>Stimulation may be evident, especially in children and geriatric patients. 
<span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span> may rarely occur. A paradoxical reaction has been reported in 
children receiving single doses of 75 mg to 125 mg orally, characterized by 
<span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">hyperexcitability</span> and <span class="product-label-link" type="condition" conceptid="4009184" conceptname="Dream anxiety disorder">nightmares</span>.</p>
<p>Atropine-like signs and symptoms – <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="4011326" conceptname="Fixed dilatation of pupil">fixed dilated pupils</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, 
as well as <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span>, may occur.</p>
<a href="http://"></a><a href="http://"></a>Treatment:<p>The treatment of overdosage with promethazine and 
dextromethorphan is essentially symptomatic and supportive. Only in cases of 
extreme overdosage or individual sensitivity do vital signs including 
respiration, pulse, blood pressure, temperature, and EKG need to be monitored. 
Activated charcoal orally or by lavage may be given, or sodium or magnesium 
sulfate orally as a cathartic. Attention should be given to the re-establishment 
of adequate respiratory exchange through provision of a patent airway and 
institution of assisted or controlled ventilation. Diazepam may be used to 
control <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>. <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">Acidosis</span> and electrolyte losses should be corrected. The 
antidotal efficacy of narcotic antagonists to dextromethorphan has not been 
established; note that any of the depressant effects of promethazine are not 
reversed by naloxone. Avoid analeptics, which may cause <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>.</p>
<p>Severe <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> usually responds to the administration of norepinephrine 
or phenylephrine. <span class="Emphasis">EPINEPHRINE SHOULD NOT BE USED,</span> 
since its use in a patient with partial adrenergic blockage may further lower 
the blood pressure.</p>
<p>Limited experience with dialysis indicates that it is not helpful.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-9"></a><p></p>
<a href="http://"></a>DOSAGE AND ADMINISTRATION<p class="First"><span class="Bold"><span class="Emphasis">Promethazine hydrochloride 
and dextromethorphan hydrobromide syrup is contraindicated for children under 2 
years of age</span></span> (see <span class="Bold"><span class="Emphasis"><a href="#section-7">WARNINGS –</a></span></span><span class="Bold"><span class="Emphasis"><a href="#section-7.1"> Black Box Warning</a></span></span> and 
<span class="Bold"><span class="Emphasis"><a href="#section-8">Use In Pediatric 
Patients</a></span></span>).</p>
<p>The average effective dose is given in the following table:</p>
<a name="i35f8c5a2-f284-447f-84b2-cdcae0331e0d"></a><table width="100%">
<col align="left" width="40%">
<col align="left" width="60%">
<tbody class="Headless">
<tr class="First">
<td align="left">
<br>Adults</td>
<td align="left">
<br><br>1 teaspoonful (5 mL) every 4 to 6 hours, <br>not to 
exceed 30 mL in 24 hours.</td>
</tr>
<tr>
<td align="left">
<br>Children 6 Years To Under 12 Years</td>
<td align="left">
<br><br>½ to 1 teaspoonful (2.5 to 5 mL) every 4 to 6 hours, 
<br>not to exceed 20 mL in 24 hours.</td>
</tr>
<tr class="Last">
<td align="left">
<br>Children 2 Years To Under 6 Years</td>
<td align="left">
<br><br>¼ to ½ teaspoonful (1.25 to 2.5 mL) every 4 to 6 hours, 
<br>not to exceed 10 mL in 24 hours.</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-10"></a><p></p>
<a href="http://"></a>HOW SUPPLIED<p class="First">This preparation is a clear syrup with yellow color and pineapple 
menthol odor, containing promethazine hydrochloride 6.25 mg/5 mL, 
dextromethorphan hydrobromide 15 mg/5 mL and alcohol 7 percent, and is available 
in 4 fluid ounce (118 mL), 8 fluid ounce (237 mL) and one pint (473 mL).</p>
<a href="http://"></a><p>Keep tightly closed. Protect from light.</p>
<p>Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature].</p>
<p>Dispense in a tight, light-resistant container with a child-resistant closure 
as defined in the USP.</p>
<a href="http://"></a><p>Manufactured for:<br><span class="Bold">QUALITEST 
PHARMACEUTICALS</span><br>Huntsville, AL 35811</p>
<p>8181650<br>R12/07-R1</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-11"></a><p></p>
<a href="http://"></a>Information For Patients:<p class="First">Promethazine and dextromethorphan may cause marked <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> or 
impair the mental and/or physical abilities required for the performance of 
potentially hazardous tasks, such as driving a vehicle or operating machinery. 
Ambulatory patients should be told to avoid engaging in such activities until it 
is known that they do not become drowsy or dizzy from promethazine and 
dextromethorphan therapy. Children should be supervised to avoid potential harm 
in bike riding or in other hazardous activities.</p>
<p>The concomitant use of alcohol or other central nervous system depressants, 
including narcotic analgesics, sedatives, hypnotics, and tranquilizers, may have 
an additive effect and should be avoided or their dosage reduced.</p>
<p>Patients should be advised to report any <span class="product-label-link" type="condition" conceptid="4319906" conceptname="Dyskinesia">involuntary muscle movements</span>.</p>
<p>Avoid prolonged exposure to the sun.</p>
<a href="http://"></a><a href="http://"></a>Drug Interactions:<a href="http://"></a><a href="http://"></a>Dextromethorphan:<p><span class="product-label-link" type="condition" conceptid="4260205" conceptname="Hyperpyrexia">Hyperpyrexia</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> have been reported 
coincident with the coadministration of monoamine oxidase (MAO) inhibitors and 
products containing dextromethorphan. Thus, concomitant administration of 
promethazine with dextromethorphan and MAO inhibitors should be avoided (see 
<span class="Bold"><span class="Emphasis"><a href="#section-6">CONTRAINDICATIONS</a></span></span>).</p>
<a href="http://"></a><a href="http://"></a>Promethazine:<a href="http://"></a><a href="http://"></a><span class="Italics">CNS Depressants – </span><p>Promethazine may increase, prolong, or intensify the sedative 
action of other central nervous system depressants, such as alcohol, 
sedatives/hypnotics (including barbiturates), narcotics, narcotic analgesics, 
general anesthetics, tricyclic antidepressants, and tranquilizers; therefore, 
such agents should be avoided or administered in reduced dosage to patients 
receiving promethazine HCl. When given concomitantly with promethazine, the dose 
of barbiturates should be reduced by at least one-half, and the dose of 
narcotics should be reduced by one-quarter to one-half. Dosage must be 
individualized. Excessive amounts of promethazine HCl relative to a narcotic may 
lead to <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span> and motor <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactivity</span> in the patient with <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>; these 
symptoms usually disappear with adequate control of the <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.</p>
<a href="http://"></a><a href="http://"></a><span class="Italics">Epinephrine – </span><p>Because of the potential for promethazine to reverse 
epinephrine's vasopressor effect, epinephrine should <span class="Emphasis">NOT</span> be used to treat <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> associated with 
promethazine <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.</p>
<a href="http://"></a><a href="http://"></a><span class="Italics">Anticholinergics – </span><p>Concomitant use of other agents with anticholinergic properties 
should be undertaken with caution.</p>
<a href="http://"></a><a href="http://"></a><span class="Italics">Monoamine Oxidase Inhibitors 
(MAOI) – </span><p>Drug interactions, including an increased incidence of 
extrapyramidal effects, have been reported when some MAOI and phenothiazines are 
used concomitantly.</p>
<a href="http://"></a><a href="http://"></a>Drug/Laboratory Test Interactions:<p>The following laboratory tests may be affected in patients who 
are receiving therapy with promethazine hydrochloride.</p>
<a href="http://"></a><a href="http://"></a>Pregnancy Tests:<p>Diagnostic pregnancy tests based on immunological reactions 
between HCG and anti-HCG may result in false-negative or false-positive 
interpretations.</p>
<a href="http://"></a><a href="http://"></a>Glucose Tolerance Test:<p>An increase in blood glucose has been reported in patients 
receiving promethazine.</p>
<a href="http://"></a><a href="http://"></a>Carcinogenesis, Mutagenesis, Impairment Of 
Fertility:<p>Long-term animal studies have not been performed to assess the 
carcinogenic potential of promethazine or of dextromethorphan. There are no 
animal or human data concerning the carcinogenicity, mutagenicity, or impairment 
of fertility with these drugs. Promethazine was nonmutagenic in the <span class="Italics"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span></span></span>  test system of 
Ames.</p>
<a href="http://"></a><a href="http://"></a>Pregnancy:<a href="http://"></a><a href="http://"></a>Teratogenic Effects – <span class="Italics">Pregnancy 
Category C:</span><p>Teratogenic effects have not been demonstrated in rat-feeding 
studies at doses of 6.25 and 12.5 mg/kg of promethazine HCl. These doses are 
from approximately 2.1 to 4.2 times the maximum recommended total daily dose of 
promethazine for a 50-kg subject, depending upon the indication for which the 
drug is prescribed. Daily doses of 25 mg/kg intraperitoneally have been found to 
produce fetal mortality in rats.</p>
<p>Specific studies to test the action of the drug on parturition, lactation, 
and development of the animal neonate were not done, but a general preliminary 
study in rats indicated no effect on these parameters. Although antihistamines 
have been found to produce fetal mortality in rodents, the pharmacological 
effects of histamine in the rodent do not parallel those in man. There are no 
adequate and well-controlled studies of promethazine in pregnant women.</p>
<p>Promethazine and dextromethorphan should be used during pregnancy only if the 
potential benefit justifies the risk to the fetus.</p>
<a href="http://"></a><a href="http://"></a>Nonteratogenic Effects:<p>Promethazine administered to a pregnant woman within two weeks of 
delivery may inhibit platelet aggregation in the newborn.</p>
<a href="http://"></a><a href="http://"></a>Labor And Delivery:<p>Limited data suggest that use of promethazine HCl during labor 
and delivery does not have an appreciable effect on the duration of labor or 
delivery and does not increase the risk of need for intervention in the newborn. 
The effect on later growth and development of the newborn is unknown. See also 
"<span class="Emphasis"><a href="#section-10.6.2"> Nonteratogenic Effects 
</a></span>".</p>
<a href="http://"></a><a href="http://"></a>Nursing Mothers:<p>It is not known whether promethazine or dextromethorphan is 
excreted in human milk.</p>
<p>Caution should be exercised when promethazine and dextromethorphan is 
administered to a nursing woman.</p>
<a href="http://"></a><a href="http://"></a>Pediatric Use:<p><span class="Bold"><span class="Emphasis">PROMETHAZINE HYDROCHLORIDE 
AND DEXTROMETHORPHAN HYDROBROMIDE SYRUP IS CONTRAINDICATED FOR USE IN PEDIATRIC 
PATIENTS LESS THAN TWO YEARS OF AGE </span></span>(see <span class="Bold"><span class="Emphasis"><a href="#section-7">WARNINGS –</a></span></span><span class="Bold"><span class="Emphasis"><a href="#section-7.1"> Black Box 
Warning</a></span></span> and <span class="Bold"><span class="Emphasis"><a href="#section-8">Use In Pediatric Patients</a></span></span>).</p>
<p>Promethazine hydrochloride and dextromethorphan hydrobromide syrup should be 
used with caution in pediatric patients 2 years of age and older (see <span class="Bold"><span class="Emphasis"><a href="#section-7">WARNINGS 
–</a></span></span><span class="Bold"><span class="Emphasis"><a href="#section-8"> 
Use In Pediatric Patients</a></span></span>).</p>
<a href="http://"></a><a href="http://"></a>Geriatric Use:<p>Clinical studies of promethazine hydrochloride and 
dextromethorphan hydrobromide syrup did not include sufficient numbers of 
subjects aged 65 and over to determine whether they respond differently from 
younger subjects. Other reported clinical experience has not identified 
differences in responses between the elderly and younger patients. In general, 
dose selection for an elderly patient should be cautious, usually starting at 
the low end of the dosing range, reflecting the greater frequency of decreased 
hepatic, renal or cardiac function, and of concomitant disease or other drug 
therapy.</p>
<p>Sedating drugs may cause <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> and over-sedation in the elderly; elderly 
patients generally should be started on low doses of promethazine hydrochloride 
and dextromethorphan hydrobromide syrup and observed closely.</p>
</div>
<div class="Warning">
<a name="section-12"></a><p></p>
<p class="First"><span class="Bold"><span class="Emphasis">WARNING:</span></span></p>
<p><span class="Bold"><span class="Emphasis">PROMETHAZINE HYDROCHLORIDE SHOULD NOT 
BE USED IN PEDIATRIC PATIENTS LESS THAN 2 YEARS OF AGE BECAUSE OF THE POTENTIAL 
FOR FATAL <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">RESPIRATORY DEPRESSION</span>.</span></span></p>
<p><span class="Bold"><span class="Emphasis">POSTMARKETING CASES OF RESPIRATORY 
<span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">DEPRESSION</span>, INCLUDING FATALITIES, HAVE BEEN REPORTED WITH USE OF PROMETHAZINE 
HYDROCHLORIDE IN PEDIATRIC PATIENTS LESS THAN 2 YEARS OF AGE. A WIDE RANGE OF 
WEIGHT-BASED DOSES OF PROMETHAZINE HYDROCHLORIDE HAVE RESULTED IN RESPIRATORY 
<span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">DEPRESSION</span> IN THESE PATIENTS.</span></span></p>
<p><span class="Bold"><span class="Emphasis">CAUTION SHOULD BE EXERCISED WHEN 
ADMINISTERING PROMETHAZINE HYDROCHLORIDE TO PEDIATRIC PATIENTS 2 YEARS OF AGE 
AND OLDER. IT IS RECOMMENDED THAT THE LOWEST EFFECTIVE DOSE OF PROMETHAZINE 
HYDROCHLORIDE BE USED IN PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER AND 
CONCOMITANT ADMINISTRATION OF OTHER DRUGS WITH RESPIRATORY DEPRESSANT EFFECTS BE 
AVOIDED.</span></span></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-12"></a><p></p>
<p class="First">Promethazine DM Label</p>
<br><p><img alt="Label Image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d2853595-d913-4332-b15f-49211a7b6667&amp;name=PromethazineDM_syrup_Label.jpg"></p>
<p><br></p>
<br><p></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PROMETHAZINE DM 		
					</strong><br><span class="contentTableReg">promethazine dm syrup</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:16590-292(NDC:0603-1586)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Dextromethorphan Hydrobromide </strong> (Dextromethorphan) </td>
<td class="formItem">Dextromethorphan Hydrobromide </td>
<td class="formItem">15 mg  in 5 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>Promethazine Hydrochloride </strong> (Promethazine) </td>
<td class="formItem">Promethazine Hydrochloride </td>
<td class="formItem">6.25 mg  in 5 mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:16590-292-04</td>
<td class="formItem">118 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA040649</td>
<td class="formItem">02/14/2006</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Stat Rx USA
							(786036330)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 10/2009<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>397f467e-aa49-455f-9e25-c61cb543a5ad</div>
<div>Set id: d2853595-d913-4332-b15f-49211a7b6667</div>
<div>Version: 1</div>
<div>Effective Time: 20091027</div>
</div>
</div> <div class="DistributorName">Stat Rx USA</div></p>
</body></html>
